Page 6,821«..1020..6,8206,8216,8226,823..6,8306,840..»

Avanir Pharmaceuticals Announces Three Poster Presentations at Consortium of MS Centers Meeting Including Preliminary …

Posted: Published on June 2nd, 2012

ALISO VIEJO, Calif., June 1, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (AVNR) today announced the presentation of three posters, including preliminary results from the PRISM patient registry, at the Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis. PRISM Registry The aims of the PRISM registry are to define pseudobulbar affect (PBA) prevalence and its quality of life (QoL) impacton patients with the associated underlying neurologic conditions of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, and traumatic brain injury (TBI). Results At the time of the data-cut a total of 3,647 patients with the six underlying neurologic conditions had enrolled in the PRISM registry. Among the enrolled patients, a total of 37.3% of all participants (n=1,361) had a positive screening score for PBA as measured by a CNS-LS13. The range of positive screening for PBA was similar across all the disease states (range of 34.7% to 40.0%); the prevalence of positive screens was also similar in the MS patient group (38.7%; n=354). The table below displays interim positive PBA screening rates of the current registry participants by underlying neurologic diagnosis. These prevalence … Continue reading

Posted in MS Treatment | Comments Off on Avanir Pharmaceuticals Announces Three Poster Presentations at Consortium of MS Centers Meeting Including Preliminary …

Researchers appealing to public for funds

Posted: Published on June 2nd, 2012

Research scientist Dr Paul Turner (left) and cell biologist Dr Jim Faed examine bone marrow stem cell colonies in the Spinal Cord Society Research Laboratory in Dunedin. Photo by Gerard O'Brien. University of Otago cell biologist, haematologist and project leader Dr Jim Faed said $1.4 million was needed to trial the use of bone marrow stem cells to stimulate insulin production in type 1 diabetics. Fundraising is being co-ordinated by the Spinal Cord Society, which had started recruiting for a related trial for spinal cord injury sufferers, to be led by Dr Faed. That trial, which would have used cells from the person's nose, is on hold, partly for lack of funds, and partly because the diabetes trial would lay the groundwork for better-designed spinal cord research. The diabetes study would be carried out in the Spinal Cord Society Research Laboratory at Otago University's Centre for Innovation in Dunedin, taking about two years. Dr Faed said recent research from the United States had "electrified" interest in using stem cells to treat type 1 diabetics. In what is known as the Chicago study, umbilical cord stem cells were shown to increase insulin production in even the most severe diabetics. Dr Faed … Continue reading

Posted in Stem Cell Research | Comments Off on Researchers appealing to public for funds

'Jack Spratt' diabetes gene identified

Posted: Published on June 2nd, 2012

Public release date: 1-Jun-2012 [ | E-mail | Share ] Contact: Andrew Gould andrew.gould@pcmd.ac.uk 44-018-843-8346 University of Exeter Type 2 diabetes is popularly associated with obesity and a sedentary lifestyle. However, just as there are obese people without type 2 diabetes, there are lean people with the disease. It has long been hypothesised that type 2 diabetes in lean people is more 'genetically driven'. A new study from a research team led by the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, which involved research institutions from around the world, has for the first time proved that lean type 2 diabetes patients have a larger genetic disposition to the disease than their obese counterparts. The study has also identified a new genetic factor associated only with lean diabetes sufferers. The study is published in PLoS Genetics. Using genetic data from genome-wide association studies, the research team tested genetic markers across the genome in approximately 5,000 lean patients with type 2 diabetes, 13,000 obese patients with the disease and 75,000 healthy controls. The team found differences in genetic enrichment between lean and obese cases, which support the hypothesis that lean diabetes sufferers have a greater genetic predisposition to the … Continue reading

Comments Off on 'Jack Spratt' diabetes gene identified

Mutant flies confirm genetic link to restless legs syndrome | Not Exactly Rocket Science

Posted: Published on June 2nd, 2012

In a lab in Atlanta, a group of flies is sleeping fitfully. Their naps are fragmented, and their legs are twitching. Their behaviour is uncannily similar to people who have a condition called restless leg syndrome (RLS). When such people are awake, they experience uncomfortable sensations in their limbs that compel them to move to get some relief. Their sleep, which is fragmented and disturbed, is characterised by the same involuntary movements. Theres a good reason for these similarities. Amanda Freeman from the Emory University School of Medicine has engineered the flies so that they have a faulty copy of BTBD9, a gene that has been linked to RLS in humans. The fact that they show the same constellation of symptoms strongly suggests that this gene is genuinely involved in the condition. In 2007, two teams of scientists linked BTBD9 to the repeated limb movements that occur during RLS. A single change in the genes sequence increased the risk of such movements by more than 50 per cent, and was probably involved in around half of such cases. One of the teams wrote that the discovery provides evidence that periodic limb movements in sleep is a genuine syndrome with a … Continue reading

Comments Off on Mutant flies confirm genetic link to restless legs syndrome | Not Exactly Rocket Science

Malta opposing EU financing for stem cell research on embryos

Posted: Published on June 2nd, 2012

Stem cell therapy may one day be used to cure disorders such as Fragile-X syndrome, or Cystic fibrosis and other genetic maladies. Matthew Vella The Maltese government wants the European Commission to abandon plans to provide funds for research activities on stem cells that involve "the destruction of human embryos". In a declaration on the ethical principles for the Horizon 2020 programme, which is an 80 billion fund for the EU's programme for research and innovation to create new jobs, the Maltese government said it wanted more detailed guidelines on the bioethical principles that will guide research programmes. Horizon 2020 will allow the financing of research on human stem cells - both adult and embryonic - as long as it is permitted by the national laws of member states. The fund however will not finance human cloning, genetic modification, or the creation of human embryos intended for the purpose of research or stem cell procurement. The European Commission does not explicitly solicit the use of human embryonic stem cells, but Horizon 2020 allows the use of human stem cells according to the objectives of the research, and only if it has the necessary approvals from the member states. The Maltese … Continue reading

Comments Off on Malta opposing EU financing for stem cell research on embryos

Biostem U.S., Corporation Presents Scientific and Medical Board of Advisors Publications

Posted: Published on June 1st, 2012

CLEARWATER, FL--(Marketwire -06/01/12)- Biostem U.S., Corporation (HAIR) (HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine science sector, has made its Scientific and Medical Board of Advisors publications available on the company website, http://www.biostemus.com. Chief Executive Officer Dwight Brunoehler stated, "The company is very proud of the many contributions its SAMBA members have made, and continue to make, to the medical community. As their publications and credentials show, this is a very prestigious and influential group. Having worked with them in past projects and now at Biostem, I know them all to be active participants in the development and guidance of the company's objectives. Their diversified areas of expertise and backgrounds are already playing a major role in assisting the company as it moves forward into the expanding field of regenerative medicine." About Biostem U.S., Corporation Biostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Biostem U.S., Corporation Presents Scientific and Medical Board of Advisors Publications

Malta opposing EU financing for stem cell research on embryos

Posted: Published on June 1st, 2012

Stem cell therapy may one day be used to cure disorders such as Fragile-X syndrome, or Cystic fibrosis and other genetic maladies. Matthew Vella The Maltese government wants the European Commission to abandon plans to provide funds for research activities on stem cells that involve "the destruction of human embryos". In a declaration on the ethical principles for the Horizon 2020 programme, which is an 80 billion fund for the EU's programme for research and innovation to create new jobs, the Maltese government said it wanted more detailed guidelines on the bioethical principles that will guide research programmes. Horizon 2020 will allow the financing of research on human stem cells - both adult and embryonic - as long as it is permitted by the national laws of member states. The fund however will not finance human cloning, genetic modification, or the creation of human embryos intended for the purpose of research or stem cell procurement. The European Commission does not explicitly solicit the use of human embryonic stem cells, but Horizon 2020 allows the use of human stem cells according to the objectives of the research, and only if it has the necessary approvals from the member states. The Maltese … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Malta opposing EU financing for stem cell research on embryos

Stemedica Takes Part in Mexican Clinical Trial

Posted: Published on June 1st, 2012

Stem cells provided by San Diego-based Stemedica Cell Technologies Inc. are expected to be used soon in a phase I/II clinical trial for chronic heart failure in Mexico. Stemedica announced May 29 that its strategic Mexico partner, Grupo Angeles Health Services, has received approval for a single-blind randomized clinical trial from Mexicos FDA equivalent regulatory agency, COFEPRIS. The trial being conducted at multiple hospital sites throughout Mexico will involve Stemedicas adult allogeneic ischemia tolerant mesenchymal stem cells delivered via intravenous infusion. The trial will involve three safety cohorts at different dosages, followed by a larger group being treated with the maximum safe dosage. The trial, set to begin on or before July 1 with 60 to 80 patients, is one of only two studies using allogeneic stem cells approved by COFEPRIS. The other study approved in 2010 was a clinical trial for ischemic stroke. We are pleased that we will be working with the largest and most prestigious private medical institution in Mexico to study Stemedicas product for this indication, said Stemedica CEO Maynard Howe in a statement. If successful, our stem cells may provide a treatment option for the millions of patients, both in Mexico and internationally, who suffer … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stemedica Takes Part in Mexican Clinical Trial

Biostem U.S., Corporation Presents Scientific and Medical Board of Advisors Publications

Posted: Published on June 1st, 2012

CLEARWATER, FL--(Marketwire -06/01/12)- Biostem U.S., Corporation (HAIR) (HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine science sector, has made its Scientific and Medical Board of Advisors publications available on the company website, http://www.biostemus.com. Chief Executive Officer Dwight Brunoehler stated, "The company is very proud of the many contributions its SAMBA members have made, and continue to make, to the medical community. As their publications and credentials show, this is a very prestigious and influential group. Having worked with them in past projects and now at Biostem, I know them all to be active participants in the development and guidance of the company's objectives. Their diversified areas of expertise and backgrounds are already playing a major role in assisting the company as it moves forward into the expanding field of regenerative medicine." About Biostem U.S., Corporation Biostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, … Continue reading

Comments Off on Biostem U.S., Corporation Presents Scientific and Medical Board of Advisors Publications

Malta opposing EU financing for stem cell research on embryos

Posted: Published on June 1st, 2012

Stem cell therapy may one day be used to cure disorders such as Fragile-X syndrome, or Cystic fibrosis and other genetic maladies. Matthew Vella The Maltese government wants the European Commission to abandon plans to provide funds for research activities on stem cells that involve "the destruction of human embryos". In a declaration on the ethical principles for the Horizon 2020 programme, which is an 80 billion fund for the EU's programme for research and innovation to create new jobs, the Maltese government said it wanted more detailed guidelines on the bioethical principles that will guide research programmes. Horizon 2020 will allow the financing of research on human stem cells - both adult and embryonic - as long as it is permitted by the national laws of member states. The fund however will not finance human cloning, genetic modification, or the creation of human embryos intended for the purpose of research or stem cell procurement. The European Commission does not explicitly solicit the use of human embryonic stem cells, but Horizon 2020 allows the use of human stem cells according to the objectives of the research, and only if it has the necessary approvals from the member states. The Maltese … Continue reading

Comments Off on Malta opposing EU financing for stem cell research on embryos

Page 6,821«..1020..6,8206,8216,8226,823..6,8306,840..»